Introducing our 2016 City2Surf Ambassador! Posted on May 20, 2016March 19, 2018 by Carly du Toit We’re excited to announce our first ever Team ACRF City2Surf Ambassador, Jessica Broome. Jess is an incredibly positive young woman with a close connection to cancer research. We are honoured to have her join us this year as our Ambassador. The last time Jess ran with Team ACRF was in 2014. Her Dad had been diagnosed with cancer eight years earlier, and she ran in support of his journey. After crossing the finish line, having raised over $1,600 for cancer research, she celebrated with a toast to her Dad. This year Jess will be running again. “I’m passionate about cancer research because I lost my Dad to cancer in April this year. A month before we lost him, I watched him walk up the hospital hallway and achieve the massive goal he had been working towards with his physio team. It seemed impossible to most of us, but he was always determined to get better. He was a fighter, not just as a fireman, but in the way he refused to give up. We were fortunate that he qualified for numerous medical trials which managed to get him through each year. For ten years they kept coming back with something new, like a magic trick that the researchers would pull out of a hat. Each new trial medication that came around, he would give it a go – no matter what. There were many years where we thought to ourselves: ‘This is it. This is the last Christmas, this is the last father’s day’…but it never was. Thanks to those trials our family was able to spend more precious time with him, which meant so much to us. Dad loved to travel, so we were able to get in some extra holidays together. He also had the chance to ensure his family, including his now 94-year-old Mum, would be okay. We even managed to squeeze in a few more parties with him! Mum and I were playing all his favourite songs on his last day, one of those songs was Margaritaville by Jimmy Buffett. We were dancing around his bed like mad women.They say that hearing is the last thing to go, so I just know this would have made him happy. He suffered many different cancers over the last ten years, but it was brain cancer that took him in the end. I feel that was the worst for him to go through. I’d really like to see a trial medication to treat this, other than steroids and pain killers. I know researchers are going to get there in time. This is why I have decided to participate in this year’s City2Surf for cancer research. It’s a great way to support a great cause. I’m not the best runner, but I really enjoy it. I think it will probably be quite a challenge as I haven’t been running for quite a while. My Dad was always telling me to get back into it, so now I’m doing it! I think he would really love that I’m getting involved. He always liked to make sure he thanked people when they helped him. So this is my thank you on his behalf. I’ll know I’ll probably cry through the finish line, but afterwards, I plan to throw one hell of a party! That’s how he would do it!” Jessica Broome ACRF City2Surf Ambassador
New Sydney cancer research centre looks into metabolic causes of cancer Posted on March 31, 2016February 25, 2018 by Carly du Toit The Centenary Institute, in partnership with the Australian Cancer Research Foundation (ACRF) and Sydney Catalyst, today opened the new ACRF Centenary Cancer Research Centre at the University of Sydney’s Charles Perkins Centre in Camperdown. The new centre will focus on two key specialist areas of cancer research – understanding the inflammatory and metabolic causes of cancer and the drivers behind cancer-driven blood clotting. By investigating these two areas, the research team hopes to unveil how changes in metabolism support cancer growth and how these changes can be controlled by new treatments and therapies. The ACRF Centenary Cancer Research Centre will be headed by Professor Philip Hogg, a world-renowned researcher whose expertise lies in the discovery of new cancer-active drugs and therapies. The centre will host a team of over 40 dedicated cancer researchers whose capability spans fundamental research to clinical trials. “I would like to thank ACRF and their supporters for funding the new centre. It will significantly expand the Centenary Institute’s capabilities in cancer research and accelerate the development of new treatments for cancer patients,” said Professor Hogg. “Having this new facility has also helped us attract a brilliant team that includes some of the world’s leading scientific minds.” ACRF’s CEO, Dr Ian Brown said, “Supporters of ACRF helped lay the foundation for this centre, a centre that will help the team at Centenary reveal key information that will help inform better cancer treatments which is an exciting step forward.” The new centre is located within the University of Sydney’s Charles Perkins Centre and is the first dedicated cancer research centre in the Royal Prince Alfred (RPA) Hospital and The University of Sydney Precinct. The establishment has been a collaborative effort lead by the Centenary Institute and included the Australian Cancer Research Foundation, Sydney Catalyst, Sydney University, the Charles Perkins Centre, RPA Hospital and Chris O’Brien Lifehouse. Image from left: ACRF Chairman Mr Tom S Dery AO, NSW Minister for Medical Research, The Hon. Pru Goward, MP, Centre Director Professor Philip Hogg and Executive Director Mathew Vadas AO.
Breakthrough in predicting the spread of cancer Posted on January 14, 2016February 25, 2018 by Carly du Toit A team of cancer researchers from Australia and the UK have bred a biosensor mouse that has enabled them to watch as pancreatic cancer cells ‘unzip’ right before they begin to spread. “Our biosensor mouse makes it possible to look at a primary tumour that has not yet spread: in real time, in 3D, and in a living tumour. Using state-of-the-art laser technology, we can see, at a molecular level, whether the contacts that hold tumour cells in place have started to unzip – and that’s a sign that the cancer is about to spread,” says Dr Paul Timpson of Sydney’s Garvan Institute of Medical Research. To understand how unzipping contributes to the spread of pancreatic cancer, the researchers implanted a genetic model of invasive pancreatic cancer. Remarkably, the researchers were able to successfully rezip these cancer cells by treating them with anti-cancer therapies, stopping the spread of cancer before it had begun. To make the biosensor, the researchers bred a mouse in which a key “zippering” protein that holds cells together – called E-cadherin – was linked to a protein from jellyfish that glows green in fluorescence microscopy. This allowed for them to pinpoint when key changes occured. Which is incredibly important given that five-year pancreatic cancer survival rates stand at just 6.1% – a figure that has barely changed in the last 40 years. “Many patients present with pancreatic cancer at a very advanced stage, when the cancer has already spread to other tissues such as the liver,” says Dr Timpson. “But sometimes, the cancer is detected before it has spread – and that’s the point where we have an opportunity to intervene and stop it in its tracks. If we give a drug early enough, we can rezip those cells together.” Dr Timpson says the most exciting part of the study was the fact that the existing treatment – an anti-invasive drug called dasatinib – allowed us to stabalise the primary tumour. “We treated mice that had developed pancreatic cancer that had yet to spread with the anti-invasive drug [and] within three days of treatment, we saw cells within the tumour had re-zippered, and the tumour had stabilised.” Similar results were achieved with a second therapy, saracatinib. “The biosensor mouse is a powerful tool for anti-cancer drug discovery,” Dr Timpson says. “It makes it possible to evaluate the effect of new therapies on tumour spread, in real time and in a system that reflects human cancer as closely as is currently possible.” Dr Timpson points out that this is just the beginning for the biosensor mouse. “We now have a model that is one step ahead of the invasion process in pancreatic cancer – but we are also already using this model in our laboratory for other aggressive and highly invasive cancer types, such as breast cancer. “Ultimately, we expect to use the biosensor mouse to explore zippering and cancer spread in a wide range of tumours throughout the body.” The Garvan Institute of Medical Research has received three ACRF cancer research grants totalling $6.13m. To read the original article, click here.
A dedicated daughter and determined mum runs toward the cures for cancer Posted on August 3, 2015March 14, 2018 by Carly du Toit Carol Tannous-Sleiman is setting an incredible example for her three young children. Having just run in the 2015 London Marathon in memory of her father, she is already gearing up for another race and continues to raise funds for cancer research. “The ACRF is an important charity for me and taking on fundraising challenges is something that I do on behalf of my father, my family and my children.” In the lead up to London she raised an astonishing $11,000. “I can’t thank everyone enough, I’m very humbled that people have donated and are here to support me. Not only does it mean a lot to me, it really means a lot to the many survivors and families out there who have lost love ones to cancer.” Her and her team of 29 staff from Greenwood Early Education Centre have been gearing up to run in this year’s City2Surf. Together they’re working with a personal trainer and planning a number of fun fundraisers in the lead up to the race, including an international party for both the kids and the parents to get involved in. Over the years Carol has participated in many famous Marathons, including Paris, Chicago and New York. London was her twelfth Full Marathon and another to cross of the Bucket List. “London was definitely in the top five – why not do a nice run, for a good cause, in a beautiful city like London?!” Before having kids, Carol had never pictured herself as a runner. To keep fit she enjoyed a daily 8km walk. “Strangely enough, it was actually my busy lifestyle that provided me with the impetus to start running. With the demands of work and parenthood, I needed to find a more time efficient form of exercise. So I thought, why don’t I just run instead of walk?” Since then she’s never looked back, and has continued to move from strength to strength. Her first real test was to run the 14km City2Surf and before long she found herself participating in 21km Half Marathons. She finally took on the full 42.2km at the Melbourne Marathon. “When you finally cross that line, it is the biggest sense of achievement. You get very tearful, it’s amazing I’m so excited to share in that moment with my team.” Click here to show Carol your support. Share your story
Running season is upon us! Posted on April 29, 2015February 25, 2018 by Carly du Toit It’s time to tie up those laces and get into a rhythm. There are four great running events coming up in locations across Australia. If you’re a seasoned runner we hope that you’ll consider running for the ACRF in your next event because it’s runners like you that help fund critical cancer research. And if you’re brand new we want to encourage you to become not just any athlete, but the one that will end cancer. When you join the ACRF running team you join an amazing group of individuals, some that have run over 10 marathons in a year! The ACRF will also be there to encourage you along the way, providing you with a wealth of resources to help you reach your goals. Sydney Half Marathon – Sunday, 17th May 2015 Perth Run for a Reason – Sunday 24th May 2015 Brisbane City2South – Sunday, 14th June 2015 Run Melbourne – Sunday, 26th July 2015 If you have any questions or would like more information please contact run@acrf.com.au or click here. Best of luck!
Millions in private funding set for top cancer scientists in Australia Posted on October 13, 2014February 25, 2018 by Carly du Toit Every year the Australian Cancer Research Foundation provides multi-million dollar grants to support research projects of the highest calibre in Australia. Last week the ACRF Research Advisory Committee met with the six shortlisted applicants to hear more about their proposed projects for research funding. Chaired by Prof. Ian Fraser AC, the Committee is made up of 14 esteemed cancer scientists. “There has been a particular interest this year in new technology for looking for molecules which fingerprint cancer cells, and for the genetic mistakes that fingerprint cancer cells,” said Prof. Frazer, following the grant interviews. This year Committee member, A/Prof. Connie Trimble from John Hopkins Hospital in Baltimore, USA, travelled to Australia to join our panel of judges over the two day interview process. Her experience and perspective on the international research stage will ensure that the successful ACRF grant recipients represent the cutting-edge of world research. The shortlisted research groups, which were selected based on their significant potential to make an impact on cancer diagnosis, treatment and/or cure, represent a need for almost $25.M in funding. The six shortlisted applicants are from all over Australia, covering research into all cancers. These are: Walter & Eliza Hall Institute, Melbourne, VIC Develop a purpose-built facility specialising in developing new targeted therapies for all types of cancer. Monash Institute of Medical Research – Prince Henry Hospital, Melbourne, VIC Expansion of an existing ACRF centre to tackle issues such as early detection, tumour diversity and drug resistance. University of Queensland Centre for Advanced Imaging, Brisbane, QLD A facility specialising in the development and validation of novel molecular imaging agents for cancer. Children’s Cancer Institute, Sydney, NSW Create an integrated and dedicated child cancer precision medicine centre, focused on delivering personalised therapies for Australian children at high risk of treatment failure. Garvan Institute of Medical Research, Sydney, NSW Build a space housing super-computer resources for a team of bioinformatics scientists, working towards the analysis of biological changes due to cancer treatment and disease progression. Sydney University Central Clinical School, Sydney, NSW Develop an ACRF imaging centre which will pioneer targeted radiotherapy and provide an opportunity for academia, medicine, industry and government to collaborate on the science and clinical practice of cancer treatment. The recipients of the 2014 grants will be announced in November. If you would like to read more about our grants process or to find out our past grants recipients please click here.[/vc_column_text][/vc_column][/vc_row]
City2Surf: the $80,000 dream Posted on August 11, 2010February 25, 2018 by Carly du Toit A very B-I-G congratulations and thank you to everyone who supported the cancer research City2Surf dream team! The ACRF dream team – led by staffers Claire, Mahsa and Natasha – is jubilant following a massive effort at last Sunday’s City2Surf which will see an extra $80,000 go directly to cancer research. The early morning start and chilly weather couldn’t keep them and close to 800 other Australian Cancer Research Foundation entrants from lining up for this annual race from the Sydney business district to Bondi beach. One of the most inspiring participants in the 80,000 strong field was Fred Pham. Mr Pham, schoolteacher and father of five young children, has only a short time to live. This did not stop him walking the 14 kilometre course with two of his sons and becoming the event’s most successful individual fundraiser. Continue reading “City2Surf: the $80,000 dream”
